BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 18984345)

  • 1. Matrix metalloproteinase inhibition reduces contraction by dupuytren fibroblasts.
    Townley WA; Cambrey AD; Khaw PT; Grobbelaar AO
    J Hand Surg Am; 2008 Nov; 33(9):1608-16. PubMed ID: 18984345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tamoxifen decreases fibroblast function and downregulates TGF(beta2) in dupuytren's affected palmar fascia.
    Kuhn MA; Wang X; Payne WG; Ko F; Robson MC
    J Surg Res; 2002 Apr; 103(2):146-52. PubMed ID: 11922728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinase inhibition modulates fibroblast-mediated matrix contraction and collagen production in vitro.
    Daniels JT; Cambrey AD; Occleston NL; Garrett Q; Tarnuzzer RW; Schultz GS; Khaw PT
    Invest Ophthalmol Vis Sci; 2003 Mar; 44(3):1104-10. PubMed ID: 12601036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced Dupuytren's disease fibroblast populated collagen lattice contraction is independent of endogenous active TGF-beta2.
    Tse R; Howard J; Wu Y; Gan BS
    BMC Musculoskelet Disord; 2004 Nov; 5(1):41. PubMed ID: 15541177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gelatinase A activity in Dupuytren's disease.
    Augoff K; Ratajczak K; Gosk J; Tabola R; Rutowski R
    J Hand Surg Am; 2006 Dec; 31(10):1635-9. PubMed ID: 17145384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dupuytren's disease: physiologic changes in nodule and cord fibroblasts through aging in vitro.
    Moyer KE; Banducci DR; Graham WP; Ehrlich HP
    Plast Reconstr Surg; 2002 Jul; 110(1):187-93; discussion 194-6. PubMed ID: 12087251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The contractile properties and responses to tensional loading of Dupuytren's disease--derived fibroblasts are altered: a cause of the contracture?
    Bisson MA; Mudera V; McGrouther DA; Grobbelaar AO
    Plast Reconstr Surg; 2004 Feb; 113(2):611-21; discussion 622-4. PubMed ID: 14758224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An insight into Dupuytren's contracture.
    Murrell GA
    Ann R Coll Surg Engl; 1992 May; 74(3):156-60; discussion 161. PubMed ID: 1616255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased contraction of glycated collagen lattices coincides with impaired matrix metalloproteinase production.
    RittiƩ L; Berton A; Monboisse JC; Hornebeck W; Gillery P
    Biochem Biophys Res Commun; 1999 Oct; 264(2):488-92. PubMed ID: 10529390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in alpha smooth muscle actin expression between fibroblasts derived from Dupuytren's nodules or cords.
    Dave SA; Banducci DR; Graham WP; Allison GM; Ehrlich HP
    Exp Mol Pathol; 2001 Oct; 71(2):147-55. PubMed ID: 11599921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elucidating the mechanism of wound contraction: rapid versus sustained myosin ATPase activity in attached-delayed-released compared with free-floating fibroblast-populated collagen lattices.
    Paul Ehrlich H; Sun B; Kainth KS; Kromah F
    Wound Repair Regen; 2006; 14(5):625-32. PubMed ID: 17014676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conditioned medium from keloid keratinocyte/keloid fibroblast coculture induces contraction of fibroblast-populated collagen lattices.
    Mukhopadhyay A; Tan EK; Khoo YT; Chan SY; Lim IJ; Phan TT
    Br J Dermatol; 2005 Apr; 152(4):639-45. PubMed ID: 15840092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic regulation of Dupuytren's fibroblast contraction in vitro.
    Rayan GM; Parizi M; Tomasek JJ
    J Hand Surg Am; 1996 Nov; 21(6):1065-70. PubMed ID: 8969433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast contraction of collagen lattices in vitro: inhibition by chronic inflammatory cell mediators.
    Ehrlich HP; Wyler DJ
    J Cell Physiol; 1983 Sep; 116(3):345-51. PubMed ID: 6885932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Keloid-derived fibroblasts have a diminished capacity to produce prostaglandin E2.
    Yeh FL; Shen HD; Lin MW; Chang CY; Tai HY; Huang MH
    Burns; 2006 May; 32(3):299-304. PubMed ID: 16487663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A complete expression profile of matrix-degrading metalloproteinases in Dupuytren's disease.
    Johnston P; Chojnowski AJ; Davidson RK; Riley GP; Donell ST; Clark IM
    J Hand Surg Am; 2007 Mar; 32(3):343-51. PubMed ID: 17336841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine manipulation of explanted Dupuytren's affected human palmar fascia.
    Kuhn MA; Payne WG; Kierney PC; Pu LL; Smith PD; Siegler K; Ko F; Wang X; Robson MC
    Int J Surg Investig; 2001; 2(6):443-56. PubMed ID: 12678125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinase inhibitors prevent a decrease in the mechanical properties of stress-deprived tendons: an in vitro experimental study.
    Arnoczky SP; Lavagnino M; Egerbacher M; Caballero O; Gardner K
    Am J Sports Med; 2007 May; 35(5):763-9. PubMed ID: 17293464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feedback inhibition of high TGF-beta1 concentrations on myofibroblast induction and contraction by Dupuytren's fibroblasts.
    Wong M; Mudera V
    J Hand Surg Br; 2006 Oct; 31(5):473-83. PubMed ID: 16875762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silicone sheeting decreases fibroblast activity and downregulates TGFbeta2 in hypertrophic scar model.
    Kuhn MA; Moffit MR; Smith PD; Lyle WG; Ko F; Meltzer DD; Robson MC
    Int J Surg Investig; 2001; 2(6):467-74. PubMed ID: 12678127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.